Published by The Health Colossus – Economics of Wellness, Insights for All
Vancouver / Doha – July 2, 2025 – Kardium Inc., a Vancouver-based medical technology company behind the innovative Globe® Pulsed Field System for the treatment of atrial fibrillation (AF), has secured USD 250 million in a transformative financing round.
The round was led by Qatar Investment Authority (QIA) alongside a distinguished consortium of new investors, including Janus Henderson Investors, MM Capital, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. Existing investors such as T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and Durable Capital Partners LP also participated. The financing included a strategic equity investment from a leading healthcare player.
“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors,” said Kevin Chaplin, CEO of Kardium. “This funding enables us to move forward with the commercial launch of the Globe System by scaling up manufacturing and building a strong commercial team. Our mission is to improve the lives of millions suffering from AF globally.”
The investment follows the promising results from Kardium’s pivotal PULSAR clinical trial, which demonstrated a 78% freedom from atrial arrhythmia at 1-year follow-up in paroxysmal AF patients, and 0% device-related primary safety events — underscoring the safety and efficacy of the Globe System.
The financing will support regulatory approvals, further expansion of manufacturing operations, and the establishment of a dedicated clinical support and commercial infrastructure ahead of the system’s anticipated commercial launch later this year.
The Globe Pulsed Field System is an advanced catheter-based platform with a 122-electrode array and proprietary software that enables rapid pulmonary vein isolation, high-definition cardiac mapping, and targeted atrial ablation—all through a single device.
About Kardium Inc.
Founded in 2007 and headquartered in Vancouver, Canada, Kardium is a privately held, innovation-driven company specializing in advanced solutions for atrial fibrillation. The company has earned recognition as one of British Columbia’s top employers and continues to collaborate with leading cardiologists and scientists worldwide.
Learn more at: www.kardium.com
